Table 2_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 3_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 4_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xls by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 1_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 6_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 5_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.docx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Functional enrichment analysis. by Andrea Salinas (4963834)

“…Finally, the extract significantly decreased concanavalin A (ConA)-induced T cell proliferation. …”

Supplementary file 1_Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study.docx by Ji-Xin Tian (21710993)

“…The use of azole antifungals was a significant factor influencing VEN concentration (P < 0.05). …”

Raw data underlying the findings in this study. by Andrew Mvula (20161161)

“…The relative bone density significantly decreased as standard length and condition factor (<i>K</i>) increased in both sexes. …”

Mutation of 1G05 epitope glycan sites impacts avidity. by Zachary T. Berndsen (9230176)

Supplementary Material for: Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by figshare admin karger (2628495)

“…Methods For this subanalysis, efficacy outcomes included a CV composite (time to CV death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for heart failure) and kidney composite (kidney failure, sustained ≥57% estimated glomerular filtration rate [eGFR] decrease from baseline over ≥4 weeks or renal death) outcome. …”

Table 1_The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system.docx by Yutong Wu (3130584)

“…Notably, we detected several potential safety signals not currently listed in the prescribing information: Malignant neoplasm progression, weight decreased, sepsis myocarditis, encephalitis and hypotension.…”

Data Sheet 1_Cytosolic phospholipase A2 links tau pathology to insulin signaling impairment in Alzheimer’s disease.pdf by Faruk Hossen (20275670)

“…Specifically, we found significant decreases in insulin receptor-α (IR-α) and insulin receptor-β (IR-β) expression, along with increased levels of phospho-insulin receptor substrate 1 at Ser307 [p-IRS-1 (Ser307)] and decreased levels of p-IRS-1 (Tyr895), compared to wild-type (WT) mice. …”

Decomposition of regional differences in CCD. by Qian Xie (43047)

“…KDE results indicate a rightward shift in the density curve of the CCD, suggesting a significant reduction in absolute disparities. …”

S1 Dataset - by Qian Xie (43047)

“…KDE results indicate a rightward shift in the density curve of the CCD, suggesting a significant reduction in absolute disparities. …”

The classification of CCD. by Qian Xie (43047)

“…KDE results indicate a rightward shift in the density curve of the CCD, suggesting a significant reduction in absolute disparities. …”

Traditional MTPM for the CCD. by Qian Xie (43047)

“…KDE results indicate a rightward shift in the density curve of the CCD, suggesting a significant reduction in absolute disparities. …”

Evaluation index system of EEC and RPH. by Qian Xie (43047)

“…KDE results indicate a rightward shift in the density curve of the CCD, suggesting a significant reduction in absolute disparities. …”

The framework of this paper. by Qian Xie (43047)

“…KDE results indicate a rightward shift in the density curve of the CCD, suggesting a significant reduction in absolute disparities. …”

Global Moran’s I for CCD (Selected Years). by Qian Xie (43047)

“…KDE results indicate a rightward shift in the density curve of the CCD, suggesting a significant reduction in absolute disparities. …”